RecruitingNot ApplicableNCT06996171

Comparative Efficacy of Magnesium Supplement and Melatonin Congener in Young Adults With Primary Insomnia


Sponsor

CMH Kharian Medical College

Enrollment

60 participants

Start Date

May 5, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

Sleep is essential for our overall health and well-being, much like food and water. It plays a vital role in numerous bodily functions. Many studies have been conducted to determine the efficacy of melatonin congeners and Mg supplements in patients with insomnia separately. This study aims to compare the efficacy of melatonin and magnesium supplements in young adults with primary insomnia. Most insomnia studies focus on older adults or individuals with comorbidities. Targeting otherwise healthy young adults brings age-specific relevance and novel insight.


Eligibility

Min Age: 18 YearsMax Age: 40 Years

Inclusion Criteria7

  • Age 18-40 years
  • Gender: Male and Females (Non-pregnant \& Non lactating)
  • Diagnosed cases of primary insomnia according to following criteria:
  • Difficulty falling asleep, staying asleep or nonrestorative sleep
  • This difficulty is present despite adequate opportunity \& circumstance to sleep
  • This impairment in sleep is associated with daytime impairment or distress
  • This sleep difficulty occurs at least 3 times per week and has been a problem for at least 1 month

Exclusion Criteria3

  • Insomnia due to a known underlying cause
  • Any psychiatric illness
  • Active use of sedative hypnotics

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGMagnesium glycinate

Tab Magnesium glycinate 500mg will be given to one group for treatment of primary insomnia

DRUGMelatonin

Tab Melatonin 10mg will be given to the other group for treatment of primary insomnia


Locations(1)

CMH Kharian Medical College

Kharan, Punjab Province, Pakistan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06996171


Related Trials